Ether‐Linked Glycerophospholipids Are Potential Chemo‐Desensitisers and Are Associated With Overall Survival in Carcinoma Patients

Wei‐Chun Chang & Wen‐Lung Ma

ABSTRACT

Lipid reprogramming in carcinoma is reported to have a role in carcinogenesis, prognosis and therapy response. The lipid reprogramming could be contributed by either autonomous or nonautonomous resources. Since the nonautonomous lipid resources contributed by lipoproteins and their receptors have been reported in epithelial ovarian cancer (EOC), the impact of autonomous lipid metabolites was unknown. This report revealed a unique lipid class, ether‐linked phosphatidyl‐ethanolamine (PE O–), which enhances chemo‐insensitivity and progression in EOC and potentially cross carcinomas. Analysis of CCLEC/GDSCC database and in‐house cell line lipidomes identified PE O– as the major lipid associated with cisplatin/paclitaxel sensitivity. In the testing of PE O– effect on cancer phenotypes, it enhanced cell growth, migratory activities and promoted cisplatin/paclitaxel insensitivity. In addition, treating AGPS inhibitor‐sensitised chemo‐cytotoxic upon cisplatin/paclitaxel treatments. Treating PE O– could reverse AGPS inhibitor chemosensitisation effect on EOC cells. At last, using TCGA‐EOC transcriptome database, the PE O– related gene expressions were positive correlated with patient prognosis in general, or in whom were treated with platin‐ or taxel‐based chemotherapies. The expressions of genes for the synthesis of PE O– aggravates therapy response in EOC patients. PE O– facilitates human carcinoma cell line growth, mobility and chemo‐insensitivity.

Funding
China Medical University Hospital Grant DMR-111-118China Medical University Hospital Grant DMR-112-098China Medical University Hospital Grant DMR-113-081China Medical University Hospital Grant DMR-113-117China Medical University Hospital Grant DMR-114-111National Health Research Institutes Grant NHRI-EX112-11110BIMinistry of Science and Technology Grant MOST 111-2314-B-039-062-MY3Ministry of Science and Technology Grant MOST 111-2320-B-039-011-National Science and Technology Council Grant NSTC 112-2320-B-039-005National Science and Technology Council Grant NSTC113-2320-B-039-061-MY3Asia University Hospital Grant AUH-11151021Asia University Hospital Grant AUH-11251003China Medical University, Taiwan Grant CMU109-MF-26China Medical University, Taiwan Grant CMU111-MF-41China Medical University, Taiwan Grant CMU112-MF-45China Medical University, Taiwan and China Medical University Hospital HsinChu Branch Grant CMUHCH-CMU-113-014China Medical University Hospital Grant DMR‐111‐118China Medical University Hospital Grant DMR‐112‐098China Medical University Hospital Grant DMR‐113‐081China Medical University Hospital Grant DMR‐113‐117China Medical University Hospital Grant DMR‐114‐111National Health Research Institutes Grant NHRI‐EX112‐11110BIMinistry of Science and Technology Grant MOST 111‐2314‐B‐039‐062‐MY3Ministry of Science and Technology Grant MOST 111‐2320‐B‐039‐011‐National Science and Technology Council Grant NSTC 112‐2320‐B‐039‐005National Science and Technology Council Grant NSTC113‐2320‐B‐039‐061‐MY3Asia University Hospital Grant AUH‐11151021Asia University Hospital Grant AUH‐11251003China Medical University, Taiwan Grant CMU109‐MF‐26China Medical University, Taiwan Grant CMU111‐MF‐41China Medical University, Taiwan Grant CMU112‐MF‐45China Medical University Grant CMUHCH‐CMU‐113‐014